Structure–activity relationship study of novel quinazoline-based 1,6-naphthyridinones as MET inhibitors with potent antitumor efficacy

Lin-Sheng Zhuo,Feng-Xu Wu,Ming-Shu Wang,Hong-Chuang Xu,Fan-Peng Yang,Yan-Guang Tian,Xing-E Zhao,Zhi-Hui Ming,Xiao-Lei Zhu,Ge-Fei Hao,Wei Huang,Xing-E. Zhao

DOI: https://doi.org/10.1016/j.ejmech.2020.112785

IF: 7.088

2020-12-01

European Journal of Medicinal Chemistry

Abstract:<p>As a privileged scaffold, the quinazoline ring is widely used in the development of EGFR inhibitors, while few quinazoline-based MET inhibitors are reported. In our ongoing efforts to develop new MET-targeted anticancer drug candidates, a series of quinazoline-based 1,6-naphthyridinone derivatives were designed, synthesized, and evaluated for their biological activities. The preliminary SARs studies indicate that the quinazoline scaffold was also acceptable for the block A of class II MET inhibitors. The further pharmacokinetic studies led to the identification of the most promising compound <strong>22a</strong> with favorable <em>in vitro</em> potency (MET, IC₅₀ = 9.0 nM), human microsomal metabolic stability (t_1/2 = 621.2 min) and oral bioavailability (<strong><em>F</em></strong> = 42%). Moreover, <strong>22a</strong> displayed good <em>in vivo</em> antitumor efficacy (IR of 81% in 75 mg/kg) in MET-positive human glioblastoma U-87 MG xenograft model. These positive results indicated that <strong>22a</strong> is a potential new MET-targeted antitumor drug lead, which is worthy of further development.</p>

chemistry, medicinal